Ipsen's Sales Growth Could Be Held Back By Generics And Currency In 2021

Dysport Down Due To COVID-19

France’s Ipsen reports a solid financial performance in 2020 but is cautious about guidance for 2021, as the mid-sized pharmaceutical company’s next rare disease candidate nears the market and it looks for early-stage assets to add to its pipeline.    

Eiffel tower iconic landmark
• Source: Shutterstock

Ipsen SA’s specialty care business expects headwinds in 2021 from a phased launch of a generic version of its somatostatin analog Somatuline (lanreotide) in Europe and a limited impact from a potential launch of octreotide (another somatostatin analog) or lanreotide generics in the US. 

Nonetheless, the mid-sized Paris-headquartered pharmaceutical company is expecting group sales to increase by more than 4% in 2021 at constant...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Earnings

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.